ORTHOPEDIATRICS CORP
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
KIDS$33.48-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows -
(In Thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| OPERATING ACTIVITIES | ||
| Net loss | $(7,805) | $(6,806) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 5,028 | 3,848 |
| Stock-based compensation | 2,799 | 2,113 |
| Fair value adjustment of contingent consideration | — | (670) |
| Accretion of acquisition installment payable | 281 | 381 |
| Deferred income taxes | (2,445) | (574) |
| Changes in certain operating assets and liabilities: | ||
| Accounts receivable - trade | 1,155 | (2,002) |
| Inventories, net | (6,631) | (5,979) |
| Prepaid expenses and other current assets | (953) | (33) |
| Accounts payable - trade | 6,562 | 5,541 |
| Accrued expenses and other liabilities | (5,049) | (1,571) |
| Other | 368 | (709) |
| Net cash used in operating activities | (6,690) | (6,461) |
| INVESTING ACTIVITIES | ||
| Acquisition of Boston O&P, net of cash acquired | (20,693) | — |
| Sale of short-term marketable securities | 23,474 | 37,250 |
| Purchases of property and equipment | (6,460) | (4,940) |
| Net cash (used in) provided by investing activities | (3,679) | 32,310 |
| FINANCING ACTIVITIES | ||
| Payments on acquisition note | (538) | — |
| Payments on mortgage notes | (35) | (36) |
| Net cash used in financing activities | (573) | (36) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 1,479 | (138) |
| NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (9,463) | 25,675 |
| Cash, cash equivalents and restricted cash, beginning of year | $33,027 | $10,462 |
| Cash, cash equivalents and restricted cash, end of period | $23,564 | $36,137 |
| SUPPLEMENTAL DISCLOSURES | ||
| Cash paid for interest | $223 | $11 |
| Transfer of instruments between property and equipment and inventory | $117 | $332 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.